

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-154US1	Application No. 10/560,098
Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1645

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LNB	AC	Cekaite et al., "Protein Arrays: A Versatile Toolbox for Target Identification and Monitoring of Patient Immune Responses," Methods Mol. Biol., 360:335-348 (2007)

Examiner Signature /Lynn Bristol/	Date Considered 10/19/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-154US1	Application No. 10/560,098
Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1645

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
LNB	AA	2004/0219643	11/04/2004	Winter et al.			
↓	AB	2006/0159673	07/20/2006	Kojima			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
LNB	AC	CA 2 331 641	11/11/1999	Canada				
↓	AD	DE 198 19 846	11/11/1999	Germany			see AC	
	AE	EP 0 774 511	05/21/1997	EPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LNB	AF	Andris-Widhopf et al., "Methods for the generation of chicken monoclonal antibody fragments by phage display," <i>J. Immunol. Methods</i> , 242:159-181 (2000)
	AG	De Jonge et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments," <i>Mol. Immunol.</i> , 32:1405-1412 (1995)
	AH	DeNardo et al., "Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy," <i>Cancer Biother. Radiopharm.</i> , 16:525-535 (2001)
	AI	Goldstein et al., "Cytolytic and Cytostatic Properties of an Anti-Human FcγRI (CD64) × Epidermal Growth Factor Bispecific Fusion Protein," <i>J. Immunol.</i> , 158:872-879 (1997)
	AJ	Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. USA</i> , 90:6444-6448 (1993)
	AK	Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Res.</i> , 19:4133-4137 (1991)
	AL	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," <i>J. Immunol. Methods</i> , 231:177-189 (1999)
	AM	Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," <i>J. Mol. Biol.</i> , 330:99-111 (2003)
	AN	Kreber et al., "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997)
	AO	Kurucz et al., "Retargeting of CTL by an Efficiently Refolded Bispecific Single-Chain Fv Dimer Produced in Bacteria," <i>J. Immunol.</i> , 154:4576-4582 (1995)
	AP	Little et al., "Of mice and men: hybridoma and recombinant antibodies," <i>Immunol. Today</i> , 21:364-370 (2000)
↓	AQ	McGuinness et al., "Phage diabody repertoires for selection of large numbers of bispecific antibody fragments," <i>Nat. Biotechnol.</i> , 14:1149-1154 (1996)

Examiner Signature /Lynn Bristol/	Date Considered 10/19/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-154US1	Application No. 10/560,098
Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1645

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LAR	AR	Merchant et al., "An efficient route to human bispecific IgG," <i>Nat. Biotechnol.</i> , 16:677-681 (1998)
	AS	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997)
	AT	Tang et al., "Selection of Linkers for a Catalytic Single-chain Antibody Using Phage Display Technology," <i>J. Biol. Chem.</i> , 271:15682-15686 (1996)
	AU	Turner et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology," <i>J. Immunol. Methods</i> , 205:43-54 (1997)
	AV	Völkel et al., "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," <i>Protein Eng.</i> , 14:815-823 (2001)

Examiner Signature /Lynn Bristol/	Date Considered 10/19/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 1 of 1

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-154US1	Application No. 10/560,098
	Applicant Taro Miyazaki et al.		
	Filing Date December 9, 2005	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
LNB	AC	WO 96/34892	11/07/1996	WIPO				
	AD	WO 98/50431	11/12/1998	WIPO				
	AE	WO 00/44788	08/03/2000	WIPO				
	AF	WO 01/44282	06/21/2001	WIPO				
	AG	WO 01/70775	09/27/2001	WIPO				
	AH	WO 03/087163	10/23/2003	WIPO			X	
	AI	2001-523971	11/27/2001	JAPAN				X

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LNB	AJ	Carter, "Bispecific human IgG by design", J. Immunol. Methods, 248:7-15 (2001)
	AK	Peipp et al., "Bispecific antibodies targeting cancer cells", Biochem. Soc. Trans., 30:507-11 (2002)
	AL	Ridgway et al., "'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization", Protein Engineering 9:617-621 (1996)
	AM	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene", J. Exp. Med., 175:217-225 (1992)
	AN	Skerra, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ", Gene, 151:131-5 (1994)
	AO	Zuo et al., "An efficient route to the production of an IgG-like bispecific antibody", Protein Engineering 13:361-367 (2000)
	AP	

Examiner Signature	/Lynn Bristol/	Date Considered	10/19/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with			